Company: ZLAB
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001628280-25-020478
Chunk: 52

Company: Zai Lab Ltd
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 52
---
 as the targeted value of the compensation under these programs. For our executive officers, we may supplement the data from our peer group with size appropriate published compensation surveys from the life sciences sector.

While the Compensation Committee considers relevant market pay practices when setting executive compensation, it does not believe it is appropriate to establish compensation levels based only on market practices. The Compensation Committee believes that compensation decisions are complex and require a deliberate review of Company and individual performance and peer compensation levels. The factors that influence the amount of compensation awarded include, but are not limited to:

• Market competition for a particular position;

• Experience and past performance inside or outside the Company;

• Roles and responsibilities within the Company;

• Tenure with the Company and associated institutional knowledge;

• Long-term potential with the Company;

<div align='center'>-38-</div>

• Innovative thinking and leadership;

• Industry expertise;

• Personal performance and contributions;

• Succession planning;

• Past and future performance objectives; and

• Value of the position within the Company.

#### 2024 EXECUTIVE COMPENSATION PROGRAM IN DETAIL

#### Annual Base Salary
The Compensation Committee seeks to maintain the annual base salaries that we pay to our new and existing named executive officers at competitive levels.

For 2024, the Board of Directors, in consideration of the recommendation by the Compensation Committee, reviewed the base salaries of chief executive officers in our peer group relative to Dr. Du’s compensation and considered Dr. Du’s capabilities, performance, and future expected contributions. Based on this analysis, the Board of Directors approved an increase to Dr. Du’s base salary to reflect her continued positive contributions and to better align this element of her compensation with the market. The Compensation Committee undertook a similar, individualized review of each other named executive officer’s capabilities, performance, roles and responsibilities, and future expected contributions, as well as considering their base salaries compared to peer group compensation data, when approving the base salaries for our other named executive officers. Based on this analysis, the Compensation Committee approved increases to base salary for Drs. Chen and Amado and Mr. Smiley, in light of their continued positive contributions and to better align this element of their compensation with the market, with a larger increase for Dr. Chen in light of her increased responsibilities related to her promotion to Chief Financial Officer in July 2023.

Below are the annual base salaries for our named executive officers in 2024 and 2023 and the percentage changes in annual base salary, where applicable.

|                    | Name |   | Base